AI Engines For more Details: Perplexity Kagi Labs You
Neuropharmacological Research: Pirenperone is commonly used in neuroscience research to study the role of serotonin receptors in various physiological and pathological processes. By selectively blocking serotonin 5-HT2 receptors, pirenperone can help researchers elucidate the functions of these receptors in the central nervous system, including their involvement in mood regulation, cognition, and behavior.
Psychopharmacological Studies: Serotonin receptors play a crucial role in the pathophysiology of psychiatric disorders such as depression, anxiety, and schizophrenia. Pirenperone, as a serotonin 5-HT2 receptor antagonist, can be used in preclinical studies to investigate the potential therapeutic effects of modulating serotonin receptor activity in these disorders. However, it is important to note that pirenperone itself is not used clinically to treat psychiatric conditions.
Experimental Tool: Pirenperone serves as an experimental tool in pharmacological and neuroscientific research to characterize the pharmacological profiles of new compounds and to explore potential drug targets for the treatment of neurological and psychiatric disorders. Its ability to selectively block serotonin 5-HT2 receptors makes it a valuable reference compound for studying the effects of serotonin receptor modulation.
Adverse Effects: Since pirenperone is not used therapeutically in humans, its specific adverse effects in clinical settings are not well-documented. However, as with any pharmacological agent targeting neurotransmitter systems, potential side effects may include alterations in mood, cognition, and behavior, as well as interactions with other medications.
Toxicity: Pirenperone is typically used in laboratory animals for research purposes, and its toxicity profile in humans is not well-established. However, as with any experimental compound, proper safety precautions should be taken when handling and administering pirenperone in laboratory settings.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.2 | 0.5 |
| Allergies | 0.2 | 0.9 | -3.5 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alzheimer's disease | 0.8 | 1.3 | -0.63 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.3 | 2.33 |
| Ankylosing spondylitis | 0.9 | 0.6 | 0.5 |
| Anorexia Nervosa | 1.1 | -1.1 | |
| Asthma | 1.1 | 1.3 | -0.18 |
| Atherosclerosis | 0.3 | 0.7 | -1.33 |
| Atrial fibrillation | 0.6 | 0.4 | 0.5 |
| Autism | 1.5 | 2.3 | -0.53 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.3 | 0.5 | -0.67 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0 | 0 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.3 | 0.7 | -1.33 |
| Cerebral Palsy | 0.5 | 0.8 | -0.6 |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Kidney Disease | 0.3 | 1 | -2.33 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | -0.8 | |
| Chronic Urticaria (Hives) | 0.5 | -0.5 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 1.9 | 0.8 | 1.37 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.8 | -0.8 | |
| COVID-19 | 0.6 | 2 | -2.33 |
| Crohn's Disease | 1 | 2.1 | -1.1 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.7 | 0.8 | -0.14 |
| Depression | 1.9 | 2.3 | -0.21 |
| Endometriosis | 0.3 | 0.8 | -1.67 |
| Epilepsy | 0.5 | 0.8 | -0.6 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 0.4 | 0.25 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 1 | -0.67 |
| gallstone disease (gsd) | 0.7 | -0.7 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.5 | 1 | -1 |
| Gout | 0.6 | 0.2 | 2 |
| Graves' disease | 0.3 | 0.8 | -1.67 |
| Gulf War Syndrome | 0.5 | -0.5 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1 | 0.7 | 0.43 |
| Heart Failure | 0.8 | 0.7 | 0.14 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 0.6 | 0.8 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
| hypertension (High Blood Pressure | 1.1 | 1.6 | -0.45 |
| Hypothyroidism | 0.2 | 0.2 | |
| Hypoxia | 0.5 | 0.1 | 4 |
| IgA nephropathy (IgAN) | 0.3 | 1.2 | -3 |
| Inflammatory Bowel Disease | 0.6 | 1.7 | -1.83 |
| Insomnia | 0.3 | 1.6 | -4.33 |
| Intelligence | 0.3 | 0.1 | 2 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.4 | 1.6 | -0.14 |
| ischemic stroke | 0.5 | 0.8 | -0.6 |
| Liver Cirrhosis | 1.1 | 1.9 | -0.73 |
| Long COVID | 0.8 | 1.8 | -1.25 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0 | 0.3 | 0 |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0.7 | -0.7 | |
| Metabolic Syndrome | 1 | 1.4 | -0.4 |
| Mood Disorders | 2.3 | 1.6 | 0.44 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
| Multiple Sclerosis | 0.5 | 1.5 | -2 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.4 | -1.4 | |
| Neuropathy (all types) | 0.2 | 0.5 | -1.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.6 | -0.33 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 2.5 | 2.2 | 0.14 |
| obsessive-compulsive disorder | 0.6 | 0.7 | -0.17 |
| Osteoarthritis | 0.3 | 0.5 | -0.67 |
| Osteoporosis | 0.8 | 0.6 | 0.33 |
| Parkinson's Disease | 1.9 | 1.3 | 0.46 |
| Polycystic ovary syndrome | 0.8 | 1 | -0.25 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.2 | 1.3 | -5.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 0.8 | 0.75 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.9 | 1.3 | -0.44 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 0.1 | 0.3 | -2 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1 | 1.2 | -0.2 |
| Systemic Lupus Erythematosus | 0.3 | 0.9 | -2 |
| Tic Disorder | 0.1 | -0.1 | |
| Tourette syndrome | 0.2 | 0.3 | -0.5 |
| Type 1 Diabetes | 0.6 | 1.1 | -0.83 |
| Type 2 Diabetes | 1 | 1.3 | -0.3 |
| Ulcerative colitis | 0.6 | 1.6 | -1.67 |
| Unhealthy Ageing | 0.3 | 0.7 | -1.33 |
| Vitiligo | 0.6 | 0.2 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
